Core Points - Nxera Pharma Co. Ltd has decided to replace its current Restricted Share Unit (RSU) Plan with an Employee Stock Ownership Plan (J-ESOP) to enhance employee engagement and provide tax benefits [1][2] - The new plan aims to mitigate the concentration of share sales that often occurs under RSU Plans and is specifically designed for employees residing in Japan [1][2] - The number of shares to be issued will remain unchanged despite the introduction of the new plan [2] Background to the Introduction - The RSU Plan was initially introduced in FY2019 to motivate Directors, Executive Officers, and Eligible Employees to align with the company's vision and strategy [2] - The decision to replace part of the RSU Plan with the J-ESOP is intended to further increase the interest of Japanese employees in share price and performance improvements [2] Overview of the Scheme - The J-ESOP is modeled after the US Employee Stock Ownership Plan (ESOP) and provides Company Shares and cash equivalents to eligible employees based on pre-established Share Benefit Rules [3] - Employees will be awarded points that can be converted into Company Shares or cash equivalents upon meeting vesting conditions [4][7] Mechanism of the Plan - The Company will establish Share Benefit Rules and entrust funds to Mizuho Trust & Banking Co., Ltd. to acquire shares for future employee grants [6] - The Trust will acquire shares through market transactions or by subscribing to newly issued shares, and will manage these as trust assets [6][4] - Voting rights will be exercised by the Trust based on instructions from the trust administrator [6]

Perspectives from Nxera’s major shareholders provide deeper insights into their investment views and confidence in the Company’s strategy Tokyo, Japan and Cambridge and London, UK, 17 November 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces the release of two video interviews with its major shareholders, available on the Company’s official YouTube channel. Nxera invited its major shareholders to share their perspectives on the Company’s strategy, operations and investment appea ...

Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference on Monday, 17 November at 12:00 p.m. GMT / 7:00 a.m. ET / 9:00 p.m. JST. During the event, Mr. Cargill will present the Company’s strategy, recent progress and expected upcoming milestones to leading global life sciences investors. The live webcast of the ‘Fireside Chat’ ...

Core Insights - Nxera Pharma has appointed Shinya Tsuzuki as the Head of Investor Relations, who will lead the IR team in Japan and report to CFO Hironoshin Nomura [1][4] - Tsuzuki has a strong background in the pharmaceutical and biotechnology sectors, having been ranked 2nd among analysts in the Nikkei Veritas rankings for 2022 and 2023, and 3rd in 2024 and 2025 [2] - The company aims to strengthen investor communications and relationships as it evolves into a next-generation biopharma business [4] Company Overview - Nxera Pharma is a technology-powered biopharma company focused on developing specialty medicines for unmet patient needs in Japan and globally [5] - The company has an extensive pipeline of over 30 active programs, targeting areas such as neurology, metabolic diseases, and immunology [6] - Nxera employs approximately 400 people across key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul, and is listed on the Tokyo Stock Exchange [7]